Regeneron's 'Champion Of Cancer Vaccines' Forges New Path
An Interview With Raquel Deering, Associate Director Of Immuno-Oncology At Regeneron
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
You may also be interested in...
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
ISA Pharmaceuticals and Regeneron have updated their collaboration to outline a potential path to market for a combination of an anticancer immunotherapeutic and the checkpoint inhibitor, cemiplimab, for HPV-associated head-and-neck cancer.
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.